Remove 2008 Remove Competition Remove Leads
article thumbnail

Roche CEO Severin Schwan to stand down after 14 years

pharmaphorum

The appointment might raise some eyebrows given Roche’s need to drive pharma sales as it copes with the loss of patent protection on an earlier generation of antibody-based therapies – now being hit by biosimilar competition – but Schwan is confident Schinecker is the right man to lead the company forward.

Sales 119
article thumbnail

Halting Europe’s essential medicines manufacturing exodus

European Pharmaceutical Review

The last paracetamol plant in Europe, closed in France in 2008 as it was no longer economically sustainable, marking the exit of paracetamol manufacturing from Europe” The closure of API manufacturing plants in Europe started in earnest 15 years ago.

Medicine 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Teva asks SCOTUS to overturn “skinny label” verdict on GSK drug

pharmaphorum

Things became litigious in 2017, when a Delaware court found that Teva’s label for its generic encouraged doctors to use the drug to treat heart failure in a way that infringed GSK’s RE40,000 patent, which was reissued by the Patent and Trademark Office (PTO) in 2008.

article thumbnail

Amarin Makes Moves towards Global Expansion of Vazkepa

Pharmaceutical Technology

AstraZeneca ’s cholesterol drug Crestor (rosuvastatin) was approved in 2003 in the US but only approved in Germany in 2008. The World Health Organization (WHO) reports that cardiovascular disease is the major leading cause of death, with 17.9 The company now faces a highly competitive generics market for its lead drug.

article thumbnail

How to Market Sensitive Healthcare Topics: A Guide

Healthcare Success

While the healthcare industry still has a long way to go, several leading organizations have responded to cultural and societal changes, challenged stereotypes, and railed against the stigma, helping pave the way toward acceptance. The Mental Health Parity and Addiction Equity Act of 2008 and the Affordable Care Act of 2010).

article thumbnail

The Traditional Pharma Model Isn’t Working – It’s Time to Evolve!

PharmaKinnex

Let’s dive into the current state of the pharma industry and learn more about what your team can do to stay ahead of the curve and the competition. PharmaKinnex knows that identifying, qualifying, and then directing leads toward a successful sale is extremely difficult in today’s environment. Sources: [link].

Pharma 52
article thumbnail

U.S. market access landscape: A push for control is erasing the boundary between payers and providers in U.S. healthcare

Clarivate

After Walgreens upped its ownership stake in the primary-care company VillageMD from 30 to 63 percent and then announced plans to operate 1,000 clinics by 2027, the writing was on the wall: to stay competitive and manage costs in CVS’ newly integrated Aetna plan, CVS could benefit by making a larger bid for primary care of its own.